4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Non-Current Deffered Revenue data on file, last reported at $2.1 million in Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue rose 389.63% year-over-year to $2.1 million in Q1 2026; TTM through Mar 2026 was $2.1 million, a 389.63% increase from a year earlier, with the FY2025 full-year figure at $745000.0, down 29.52% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $2.1 million, up from $745000.0 in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for FDMT reached as high as $2.1 million in Q1 2026 and fell as low as $219000.0 in Q2 2025.
• Historically, Non-Current Deffered Revenue has averaged $1.1 million across 5 years, with a median of $1.1 million in 2024.
• Across the five-year window, Non-Current Deffered Revenue slumped 84.94% in 2022 and soared 389.63% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $1.1 million in 2022, then fell by 9.67% to $972000.0 in 2023, then advanced by 8.74% to $1.1 million in 2024, then decreased by 29.52% to $745000.0 in 2025, then soared by 185.23% to $2.1 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $2.1 million in Q1 2026, $745000.0 in Q4 2025, and $835000.0 in Q3 2025.